https://www.selleckchem.com/products/nhwd-870.html
Treatment compliance and levels of satisfaction of both the parents and the investigators were high. Overall, 33.3% of patients (7/21) experienced at least one adverse event (AE). Only one patient (4.8%) experienced a drug-related AE (abdominal pain, upper). CONCLUSIONS A 2 mg/kg daily dose of the new oral ferrous sulfate heptahydrate solution provides substantial therapeutic benefit with high levels of tolerability in young children with mild or moderate IDA. This article is protected by copyright. All rights reserved.Switzerland is a
Gefällt mir
Kommentar
Teilen
